Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced upcoming presentations of new interim data from their Phase 1 clinical trial of soquelitinib for atopic dermatitis treatment. The data, from Cohorts 1-3 of the randomized, double-blind, placebo-controlled trial, will be presented at the Society for Investigative Dermatology (SID) 2025 Annual Meeting in San Diego.
Dr. Albert S. Chiou from Stanford University Medical Center will present the findings titled 'Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action' through both an oral presentation and poster session on May 8-10, 2025.
The company will discuss these results during their first quarter 2025 business update conference call scheduled for May 8, 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato le prossime presentazioni dei nuovi dati preliminari del loro studio clinico di Fase 1 su soquelitinib per il trattamento della dermatite atopica. I dati, provenienti dai Gruppi 1-3 dello studio randomizzato, in doppio cieco e controllato con placebo, saranno presentati al Society for Investigative Dermatology (SID) 2025 Annual Meeting a San Diego.
Il dott. Albert S. Chiou del Stanford University Medical Center presenterà i risultati intitolati 'Selective Soquelitinib, un inibitore selettivo di ITK che dimostra attività nella fase 1 dello studio clinico sulla dermatite atopica tramite un nuovo meccanismo d’azione' attraverso una presentazione orale e una sessione poster dall’8 al 10 maggio 2025.
L’azienda discuterà questi risultati durante la conference call di aggiornamento aziendale del primo trimestre 2025, prevista per l’8 maggio 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha anunciado próximas presentaciones de nuevos datos provisionales de su ensayo clínico de Fase 1 sobre soquelitinib para el tratamiento de la dermatitis atópica. Los datos, de los Grupos 1-3 del ensayo aleatorizado, doble ciego y controlado con placebo, se presentarán en la Reunión Anual 2025 de la Society for Investigative Dermatology (SID) en San Diego.
El Dr. Albert S. Chiou del Stanford University Medical Center presentará los hallazgos titulados 'Selective Soquelitinib, un inhibidor selectivo de ITK que demuestra actividad en el ensayo clínico de fase 1 para dermatitis atópica mediante un nuevo mecanismo de acción' mediante una presentación oral y una sesión de pósters del 8 al 10 de mayo de 2025.
La compañía discutirá estos resultados durante su llamada de actualización empresarial del primer trimestre de 2025, programada para el 8 de mayo de 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS)는 아토피 피부염 치료를 위한 소퀠리티닙의 1상 임상시험 중간 데이터 발표를 예고했습니다. 무작위 배정, 이중 맹검, 위약 대조 시험의 1~3군에서 나온 데이터는 2025년 Society for Investigative Dermatology (SID) 연례회의에서 샌디에이고에서 발표될 예정입니다.
스탠포드 대학 의료센터의 알버트 S. 치우 박사가 '선택적 ITK 억제제인 선택적 소퀠리티닙이 새로운 작용 기전으로 아토피 피부염 1상 임상시험에서 활성을 보인다'라는 제목으로 2025년 5월 8일부터 10일까지 구두 발표와 포스터 세션을 진행할 예정입니다.
회사는 2025년 1분기 실적 업데이트 컨퍼런스 콜에서 이 결과를 2025년 5월 8일에 논의할 계획입니다.
Corvus Pharmaceuticals (NASDAQ : CRVS) a annoncé les prochaines présentations de nouvelles données intermédiaires issues de leur essai clinique de phase 1 sur soquelitinib pour le traitement de la dermatite atopique. Les données, provenant des cohortes 1 à 3 de l’essai randomisé, en double aveugle, contrôlé par placebo, seront présentées lors de la Réunion Annuelle 2025 de la Society for Investigative Dermatology (SID) à San Diego.
Le Dr Albert S. Chiou du Stanford University Medical Center présentera les résultats intitulés « Selective Soquelitinib, un inhibiteur sélectif de l’ITK, démontre une activité dans l’essai clinique de phase 1 sur la dermatite atopique via un nouveau mécanisme d’action » lors d’une présentation orale et d’une session poster du 8 au 10 mai 2025.
L’entreprise discutera de ces résultats lors de sa conférence téléphonique de mise à jour commerciale du premier trimestre 2025, prévue le 8 mai 2025.
Corvus Pharmaceuticals (NASDAQ: CRVS) hat die bevorstehenden Präsentationen neuer Zwischenergebnisse aus ihrer Phase-1-Studie zu Soquelitinib zur Behandlung der atopischen Dermatitis angekündigt. Die Daten aus den Kohorten 1-3 der randomisierten, doppelblinden, placebokontrollierten Studie werden auf dem Society for Investigative Dermatology (SID) Jahreskongress 2025 in San Diego vorgestellt.
Dr. Albert S. Chiou vom Stanford University Medical Center wird die Ergebnisse mit dem Titel 'Selective Soquelitinib, ein selektiver ITK-Inhibitor, zeigt Wirksamkeit in der Phase-1-Studie zur atopischen Dermatitis durch einen neuartigen Wirkmechanismus' sowohl in einer mündlichen Präsentation als auch in einer Postersession vom 8. bis 10. Mai 2025 vorstellen.
Das Unternehmen wird diese Ergebnisse während der Telefonkonferenz zum Geschäftsupdate für das erste Quartal 2025 am 8. Mai 2025 besprechen.
- None.
- None.
Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting
Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting, which is taking place May 7-10, 2025 in San Diego, CA.
Presentation details are as follows:
Title: Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action
Abstract #: 0437
Presenter: Albert S. Chiou, M.D., MBA, Clinical Associate Professor, Dermatology and Director of Clinical Research in the Department of Dermatology at Stanford University Medical Center
Poster Presentation Date and Time: May 8, 2025 from 4:30 – 6:00 pm PT
Oral Presentation Date and Time: May 10, 2025 from 9:50 – 10:00 am PT
First Quarter 2025 Financial Results Conference Call and Webcast
Corvus will present details on the new data from the soquelitinib Phase 1 clinical trial during the Company’s first quarter 2025 business update conference call and webcast, which is scheduled for Thursday, May 8, 2025 at 4:30 pm ET / 1:30 pm PT. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 60 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
What are the key findings from Corvus Pharmaceuticals' (CRVS) Phase 1 trial of soquelitinib for atopic dermatitis?
How does soquelitinib work in treating atopic dermatitis?
When will CRVS present the soquelitinib Phase 1 trial results?
What type of clinical trial is CRVS conducting for soquelitinib?
